These data suggest that PARN downregulation allowed activation of post-transcriptional events normally kept under its control, which could contribute to cancer development and progression in which PLD2 has already been implicated (Kang et al., 2009; Park and Min do, 2011; Henkels et al., 2013; Kang et al., 2015). Here, PLD2 is linked to cancer.